Form D · Biotechnology
MDI Therapeutics, Inc.
Novi, MI · CIK 0001732863
Offering snapshot reported Mar 8, 2022 · SEC filing
- Reported sold
- $1.69M Offering amount: $9.69M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 28, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 8, 2022 | Initial | $1,685,855 | No comparison | 3 | SEC filing |
| Feb 28, 2018 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-436269
Source: Form D, filed Mar 8, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Stephen C Benoit | Director, Executive |
| Duane E Day | Executive |
| David Ginsburg | Director |
| Daniel A Lawrence | Executive |
| Daniel Lawrence, Ph.D. | Director, Executive |
| Grazia Piizzi | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
46430 Peary Court Suite 600
Novi, MI, 48377
Novi, MI, 48377